[{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT04-01 Phase I adult clinical trials,,"},{"Key":"Keywords","Value":"Lung cancer: non-small cell,Therapeutic cancer vaccine,Immune checkpoint, pembrolizumab,Allogeneic Plasmacytoid dendritic cells,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>W. Theelen<\/b><sup>1<\/sup>, M. Perol<sup>2<\/sup>, K. Cuppens<sup>3<\/sup>, I. Demedts<sup>4<\/sup>, F. Borm<sup>5<\/sup>, B. Biesma<sup>6<\/sup>, E. Wauters<sup>7<\/sup>, B. Colinet<sup>8<\/sup>, E.-L. Buchmeier<sup>9<\/sup>, F. Althoff<sup>10<\/sup>, E. Pons-Tostivint<sup>11<\/sup>, C. Van de Kerkhove<sup>12<\/sup>, D. Moro-Sibilot<sup>13<\/sup>, A. Sibille<sup>14<\/sup>, S. Derijcke<sup>15<\/sup>, M. Skrzypski<sup>16<\/sup>, J. Plumas<sup>17<\/sup>, B. De Vos<sup>17<\/sup>, C. Debruyne<sup>17<\/sup>, F. Cantero<sup>17<\/sup>, S. Adriaenssens<sup>17<\/sup>, F. Renard<sup>17<\/sup>, J. Vansteenkiste<sup>7<\/sup>; <br\/><sup>1<\/sup>Netherlands Cancer Institute, Amsterdam, Netherlands, <sup>2<\/sup>Leon Berard Cancer Center, Lyon, France, <sup>3<\/sup>Jessa Hospital, Hasselt, Belgium, <sup>4<\/sup>AZ Delta, Roeselare, Belgium, <sup>5<\/sup>Leiden University Medical Center, Leiden, Belgium, <sup>6<\/sup>Jeroen Bosch Ziekenhuis, Hertogenbosch, Netherlands, <sup>7<\/sup>University Hospital KU, Leuven, Belgium, <sup>8<\/sup>Grand hopital de Charleroi (GHdC), Charleroi, Belgium, <sup>9<\/sup>Lungenklinic Koeln-Merheim, Koeln-Merheim, Germany, <sup>10<\/sup>Universtity Hospital Frankfurt, Frankfurt, Germany, <sup>11<\/sup>CHU de Nantes, Nantes, France, <sup>12<\/sup>Vitaz, Sint-Niklaas, Belgium, <sup>13<\/sup>CHU de Grenoble, Grenoble, France, <sup>14<\/sup>University Hospital of Liege, Liege, Belgium, <sup>15<\/sup>AZ Groeninge, Kortrijk, Belgium, <sup>16<\/sup>Medical University of Gdansk, Gdansk, Poland, <sup>17<\/sup>PDC*Line Pharma, Liege, Belgium","CSlideId":"","ControlKey":"41495dfb-08d5-4aba-a461-8e26ee4c0d7b","ControlNumber":"10712","DisclosureBlock":"&nbsp;<b>W. Theelen, <\/b> None..<br><b>M. Perol, <\/b> None..<br><b>K. Cuppens, <\/b> None..<br><b>I. Demedts, <\/b> None..<br><b>F. Borm, <\/b> None..<br><b>B. Biesma, <\/b> None..<br><b>E. Wauters, <\/b> None..<br><b>B. Colinet, <\/b> None..<br><b>E. Buchmeier, <\/b> None..<br><b>F. Althoff, <\/b> None..<br><b>E. Pons-Tostivint, <\/b> None..<br><b>C. Van de Kerkhove, <\/b> None..<br><b>D. Moro-Sibilot, <\/b> None..<br><b>A. Sibille, <\/b> None..<br><b>S. Derijcke, <\/b> None..<br><b>M. Skrzypski, <\/b> None.&nbsp;<br><b>J. Plumas, <\/b> <br><b>PDC*Line Pharma<\/b> Employment, Stock Option, Travel, Patent. <br><b>B. De Vos, <\/b> <br><b>PDC*Line Pharma<\/b> Employment. <br><b>C. Debruyne, <\/b> <br><b>PDC*Line Pharma<\/b> Employment, Stock Option. <br><b>F. Cantero, <\/b> <br><b>PDC*Line Pharma<\/b> Employment, Stock Option, Travel. <br><b>S. Adriaenssens, <\/b> <br><b>PDC*Line Pharma<\/b> Employment. <br><b>F. Renard, <\/b> <br><b>PDC*Line Pharma<\/b> Employment.<br><b>J. Vansteenkiste, <\/b> None.","End":"4\/7\/2024 3:10:00 PM","HasWebcast":null,"Highlights":[],"Id":"11399","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"1","PosterboardNumber":"","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT021","PresenterBiography":null,"PresenterDisplayName":"Willemijn Theelen, MD, PhD","PresenterKey":"3bbcefcd-a516-4690-830b-ecb81a29acd9","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT021. Preliminary clinical results of a therapeutic cancer vaccine PDC*lung01 in combination with anti-PD-1 in patients (pts) with stage IV NSCLC","SearchResultFooter":"","SearchResultHeader":"Apr  7 2024  3:00PM","SessionId":"663","SessionOnDemand":"False","SessionTitle":"Cancer Vaccines: Ready for Prime Time?","ShowChatLink":"false","Start":"4\/7\/2024 3:00:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Preliminary clinical results of a therapeutic cancer vaccine PDC*lung01 in combination with anti-PD-1 in patients (pts) with stage IV NSCLC","Topics":null,"cSlideId":""},{"Abstract":"There is no abstract associated with this presentation.","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null},{"Icon":null,"Label":"View Video","SubType":null,"Type":"ViewPlayer","Url":null},{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Other","AdditionalFields":[{"Key":"Topics","Value":",,"},{"Key":"Keywords","Value":",,,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":[],"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":". ","CSlideId":"","ControlKey":"552748c6-0716-4017-a436-c261a4e9d371","ControlNumber":"12145","DisclosureBlock":"","End":"4\/7\/2024 3:15:00 PM","HasWebcast":null,"Highlights":[],"Id":"11844","IsPresentation":"False","IsSessionOrganizer":"False","Keywords":null,"MediaSource":"None","OtherContent":null,"PlayerUrl":null,"PlayerUrlReason":null,"PositionInSession":"2","PosterboardNumber":"","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"","PresenterBiography":null,"PresenterDisplayName":null,"PresenterKey":null,"PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"Discussion","SearchResultFooter":"","SearchResultHeader":"Apr  7 2024  3:00PM","SessionId":"663","SessionOnDemand":"False","SessionTitle":"Cancer Vaccines: Ready for Prime Time?","ShowChatLink":"false","Start":"4\/7\/2024 3:10:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Discussion","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT04-01 Phase I adult clinical trials,,"},{"Key":"Keywords","Value":"Pancreatic cancer,Premalignancy,Vaccines,Prevention,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>S. D. Haldar<\/b><sup>1<\/sup>, A. Huff<sup>1<\/sup>, E. Abou Diwan<sup>2<\/sup>, A. Ferguson<sup>1<\/sup>, C. Judkins<sup>1<\/sup>, J. Lu<sup>3<\/sup>, H. Wang<sup>3<\/sup>, H. Sinan<sup>4<\/sup>, C. Thoburn<sup>1<\/sup>, K. M. Bever<sup>1<\/sup>, M. Yarchoan<sup>1<\/sup>, A. M. Thomas<sup>1<\/sup>, J. M. Nauroth<sup>1<\/sup>, D. A. Laheru<sup>1<\/sup>, M. G. Goggins<sup>5<\/sup>, E. M. Jaffee<sup>1<\/sup>, N. S. Azad<sup>1<\/sup>, N. Zaidi<sup>1<\/sup>; <br\/><sup>1<\/sup>Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, <sup>2<\/sup>Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, <sup>3<\/sup>Division of Biostatistics and Bioinformatics, Johns Hopkins University School of Medicine, Baltimore, MD, <sup>4<\/sup>Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, <sup>5<\/sup>Departments of Pathology, Oncology, and Medicine, Johns Hopkins University School of Medicine, Baltimore, MD","CSlideId":"","ControlKey":"383f2de0-ded5-4fc6-aa48-e3f7d0c5baa7","ControlNumber":"9507","DisclosureBlock":"&nbsp;<b>S. D. Haldar, <\/b> None..<br><b>A. Huff, <\/b> None..<br><b>E. Abou Diwan, <\/b> None..<br><b>A. Ferguson, <\/b> None..<br><b>C. Judkins, <\/b> None..<br><b>J. Lu, <\/b> None..<br><b>H. Wang, <\/b> None..<br><b>H. Sinan, <\/b> None..<br><b>C. Thoburn, <\/b> None..<br><b>K. M. Bever, <\/b> None.&nbsp;<br><b>M. Yarchoan, <\/b> <br><b>Genentech<\/b> Grant\/Contract, Other, Consultant. <br><b>Exelixis<\/b> Grant\/Contract, Other, Consultant. <br><b>Eisai<\/b> Other, Consultant. <br><b>AstraZeneca<\/b> Other, Consultant. <br><b>Geneos<\/b> Other, Consultant. <br><b>Replimune<\/b> Other, Consultant. <br><b>Bristol Myers Squibb<\/b> Grant\/Contract. <br><b>Incyte<\/b> Grant\/Contract. <br><b>Adventris<\/b> Other, Co-Founder.<br><b>A. M. Thomas, <\/b> None..<br><b>J. M. Nauroth, <\/b> None..<br><b>D. A. Laheru, <\/b> None..<br><b>M. G. Goggins, <\/b> None.&nbsp;<br><b>E. M. Jaffee, <\/b> <br><b>Abmeta<\/b> Other, Other Support. <br><b>Achilles<\/b> Other, Personal Fees. <br><b>Parker Institute<\/b> Other, Personal Fees. <br><b>CPRIT<\/b> Other, Personal Fees. <br><b>Surge<\/b> Other, Personal Fees. <br><b>HDT Biosciences<\/b> Other, Personal Fees. <br><b>Lustgarten Foundation<\/b> Grant\/Contract. <br><b>Genentech<\/b> Grant\/Contract. <br><b>Mestag<\/b> Other, Personal Fees. <br><b>Medical Home Group<\/b> Other, Personal Fees. <br><b>Bristol Myers Squibb<\/b> Grant\/Contract. <br><b>Break Through Cancer<\/b> Grant\/Contract. <br><b>N. S. Azad, <\/b> <br><b>Bristol Myers Squibb<\/b> Grant\/Contract. <br><b>Merck<\/b> Grant\/Contract, Other, Consultant. <br><b>Incyte<\/b> Grant\/Contract. <br><b>Syndax<\/b> Grant\/Contract. <br><b>Intensity<\/b> Grant\/Contract. <br><b>Bayer<\/b> Grant\/Contract. <br><b>EMD Serono<\/b> Grant\/Contract, Other, Consultant. <br><b>AstraZeneca<\/b> Other, Consultant. <br><b>N. Zaidi, <\/b> <br><b>Genentech<\/b> Other, Consultant. <br><b>Adventris Pharmaceuticals<\/b> Other, Other Support. <br><b>Bristol Myers Squibb<\/b> Grant\/Contract.","End":"4\/7\/2024 3:25:00 PM","HasWebcast":null,"Highlights":[],"Id":"11400","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"3","PosterboardNumber":"","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT022","PresenterBiography":null,"PresenterDisplayName":"Saurav Haldar, MD","PresenterKey":"7ae918cd-d2ec-4be0-8992-6c314a942238","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT022. Mutant KRAS peptide-based vaccine in patients at high risk of developing pancreatic cancer: Preliminary analysis from a phase I study <b><\/b>","SearchResultFooter":"","SearchResultHeader":"Apr  7 2024  3:00PM","SessionId":"663","SessionOnDemand":"False","SessionTitle":"Cancer Vaccines: Ready for Prime Time?","ShowChatLink":"false","Start":"4\/7\/2024 3:15:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Mutant KRAS peptide-based vaccine in patients at high risk of developing pancreatic cancer: Preliminary analysis from a phase I study <b><\/b>","Topics":null,"cSlideId":""},{"Abstract":"There is no abstract associated with this presentation.","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null},{"Icon":null,"Label":"View Video","SubType":null,"Type":"ViewPlayer","Url":null},{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Other","AdditionalFields":[{"Key":"Topics","Value":",,"},{"Key":"Keywords","Value":",,,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":[],"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":". ","CSlideId":"","ControlKey":"ef35b75a-e317-4864-baea-73810aa0fdcd","ControlNumber":"12146","DisclosureBlock":"","End":"4\/7\/2024 3:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"11845","IsPresentation":"False","IsSessionOrganizer":"False","Keywords":null,"MediaSource":"None","OtherContent":null,"PlayerUrl":null,"PlayerUrlReason":null,"PositionInSession":"4","PosterboardNumber":"","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"","PresenterBiography":null,"PresenterDisplayName":null,"PresenterKey":null,"PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"Discussion","SearchResultFooter":"","SearchResultHeader":"Apr  7 2024  3:00PM","SessionId":"663","SessionOnDemand":"False","SessionTitle":"Cancer Vaccines: Ready for Prime Time?","ShowChatLink":"false","Start":"4\/7\/2024 3:25:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Discussion","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT04-01 Phase I adult clinical trials,,"},{"Key":"Keywords","Value":"Prostate cancer,Immunotherapy,Tumor microenvironment,Immunostimulation,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>S. S. Nair<\/b><sup>1<\/sup>, D. Chakravarty<sup>1<\/sup>, S. Balan<sup>1<\/sup>, A. Hakansson<sup>2<\/sup>, M. Duval<sup>3<\/sup>, E. Davicioni<sup>2<\/sup>, Y. Liu<sup>2<\/sup>, S. Bhardwaj<sup>1<\/sup>, T. H. Thin<sup>1<\/sup>, M. Garcia-barros<sup>1<\/sup>, K. Haines<sup>1<\/sup>, M. Al Shaarani<sup>4<\/sup>, R. Weil<sup>1<\/sup>, M. Meseck<sup>1<\/sup>, P. Ratnani<sup>1<\/sup>, M. Fatterpekar<sup>1<\/sup>, I. Jambor<sup>1<\/sup>, E. Gonzalez-Gugel<sup>1<\/sup>, A. Farkas<sup>1<\/sup>, V. Wagaskar<sup>1<\/sup>, K. Schlussel<sup>1<\/sup>, C. Pasat-karasik<sup>1<\/sup>, K. Bhatt<sup>1<\/sup>, Z. Dovey<sup>1<\/sup>, A. Pedraza<sup>1<\/sup>, A. Gupta<sup>1<\/sup>, D. Lundon<sup>1<\/sup>, A. Peros<sup>1<\/sup>, S. Parekh<sup>1<\/sup>, L. Davenport<sup>1<\/sup>, X. Zhang<sup>1<\/sup>, R. Gupta<sup>1<\/sup>, M. Robison<sup>1<\/sup>, C. Knauer<sup>1<\/sup>, E. Ellis<sup>1<\/sup>, D. Rykunov<sup>1<\/sup>, B. Reva<sup>1<\/sup>, B. Padanilam<sup>1<\/sup>, M. D. Galsky<sup>1<\/sup>, R. Brody<sup>1<\/sup>, M. Menon<sup>1<\/sup>, A. Salazar<sup>5<\/sup>, N. Bhardwaj<sup>1<\/sup>, A. K. Tewari<sup>1<\/sup>; <br\/><sup>1<\/sup>Icahn School of Medicine at Mount Sinai, New York, NY, <sup>2<\/sup>Veracyte Inc, South San Francisco, CA, <sup>3<\/sup>Double Strand, Acton, MA, <sup>4<\/sup>UT Health Houston, Houston, TX, <sup>5<\/sup>Oncovir Inc, Winchester, VA","CSlideId":"","ControlKey":"4c522a27-f2ee-4b65-b3b5-ca6231751a99","ControlNumber":"10321","DisclosureBlock":"&nbsp;<b>S. S. Nair, <\/b> None..<br><b>D. Chakravarty, <\/b> None..<br><b>S. Balan, <\/b> None..<br><b>A. Hakansson, <\/b> None..<br><b>M. Duval, <\/b> None..<br><b>E. Davicioni, <\/b> None..<br><b>Y. Liu, <\/b> None..<br><b>S. Bhardwaj, <\/b> None..<br><b>T. H. Thin, <\/b> None..<br><b>M. Garcia-barros, <\/b> None..<br><b>K. Haines, <\/b> None..<br><b>M. Al Shaarani, <\/b> None..<br><b>R. Weil, <\/b> None..<br><b>M. Meseck, <\/b> None..<br><b>P. Ratnani, <\/b> None..<br><b>M. Fatterpekar, <\/b> None..<br><b>I. Jambor, <\/b> None..<br><b>E. Gonzalez-Gugel, <\/b> None..<br><b>A. Farkas, <\/b> None..<br><b>V. Wagaskar, <\/b> None..<br><b>K. Schlussel, <\/b> None..<br><b>C. Pasat-karasik, <\/b> None..<br><b>K. Bhatt, <\/b> None..<br><b>Z. Dovey, <\/b> None..<br><b>A. Pedraza, <\/b> None..<br><b>A. Gupta, <\/b> None..<br><b>D. Lundon, <\/b> None..<br><b>A. Peros, <\/b> None..<br><b>S. Parekh, <\/b> None..<br><b>L. Davenport, <\/b> None..<br><b>X. Zhang, <\/b> None..<br><b>R. Gupta, <\/b> None..<br><b>M. Robison, <\/b> None..<br><b>C. Knauer, <\/b> None..<br><b>E. Ellis, <\/b> None..<br><b>D. Rykunov, <\/b> None..<br><b>B. Reva, <\/b> None..<br><b>B. Padanilam, <\/b> None..<br><b>M. D. Galsky, <\/b> None..<br><b>R. Brody, <\/b> None..<br><b>M. Menon, <\/b> None..<br><b>A. Salazar, <\/b> None..<br><b>N. Bhardwaj, <\/b> None..<br><b>A. K. Tewari, <\/b> None.","End":"4\/7\/2024 3:40:00 PM","HasWebcast":null,"Highlights":[],"Id":"11401","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"5","PosterboardNumber":"","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT023","PresenterBiography":null,"PresenterDisplayName":"Sujit Nair, PhD","PresenterKey":"26fbeb9b-2a9a-4480-9402-e7d978550bbe","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT023. Prostate cancer<i> in situ<\/i> autovaccination with the intratumoral viral mimic poly-ICLC: Making a cold tumor hot","SearchResultFooter":"","SearchResultHeader":"Apr  7 2024  3:00PM","SessionId":"663","SessionOnDemand":"False","SessionTitle":"Cancer Vaccines: Ready for Prime Time?","ShowChatLink":"false","Start":"4\/7\/2024 3:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Prostate cancer<i> in situ<\/i> autovaccination with the intratumoral viral mimic poly-ICLC: Making a cold tumor hot","Topics":null,"cSlideId":""},{"Abstract":"There is no abstract associated with this presentation.","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null},{"Icon":null,"Label":"View Video","SubType":null,"Type":"ViewPlayer","Url":null},{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Other","AdditionalFields":[{"Key":"Topics","Value":",,"},{"Key":"Keywords","Value":",,,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":[],"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":". ","CSlideId":"","ControlKey":"7e58f20f-4567-4004-953c-87aa32b0cbc3","ControlNumber":"12147","DisclosureBlock":"","End":"4\/7\/2024 3:45:00 PM","HasWebcast":null,"Highlights":[],"Id":"11846","IsPresentation":"False","IsSessionOrganizer":"False","Keywords":null,"MediaSource":"None","OtherContent":null,"PlayerUrl":null,"PlayerUrlReason":null,"PositionInSession":"6","PosterboardNumber":"","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"","PresenterBiography":null,"PresenterDisplayName":null,"PresenterKey":null,"PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"Discussion","SearchResultFooter":"","SearchResultHeader":"Apr  7 2024  3:00PM","SessionId":"663","SessionOnDemand":"False","SessionTitle":"Cancer Vaccines: Ready for Prime Time?","ShowChatLink":"false","Start":"4\/7\/2024 3:40:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Discussion","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT05-01 Phase II adult clinical trials,,"},{"Key":"Keywords","Value":"Vaccines,Combination therapy,Immuno-oncology,Cancer vaccine,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"H. Shaw<sup>1<\/sup>, P. Patel<sup>2<\/sup>, M. Payne<sup>3<\/sup>, S. Kumar<sup>4<\/sup>, M. Highley<sup>5<\/sup>, K. Prasad<sup>6<\/sup>, R. Board<sup>6<\/sup>, C. Barlow<sup>7<\/sup>, S. Danson<sup>8<\/sup>, R. Miller<sup>9<\/sup>, G. Goodhew<sup>9<\/sup>, F. Master<sup>9<\/sup>, <b>L. Durrant<\/b><sup>9<\/sup>; <br\/><sup>1<\/sup>Mount Vernon Cancer Centre, Northwood, United Kingdom, <sup>2<\/sup>Nottingham Hospitals University Trust, Nottingham, United Kingdom, <sup>3<\/sup>Churchill Hospital, Oxford, United Kingdom, <sup>4<\/sup>Velindre Cancer Centre, Cardiff, United Kingdom, <sup>5<\/sup>Derriford Hospital, Plymouth, United Kingdom, <sup>6<\/sup>Royal Preston Hospital, Preston, United Kingdom, <sup>7<\/sup>Musgrove Park Hospital, Taunton, United Kingdom, <sup>8<\/sup>Weston Park Cancer Centre, Sheffield, United Kingdom, <sup>9<\/sup>SCANCELL Ltd, Oxford, United Kingdom","CSlideId":"","ControlKey":"7718a088-afe8-4c40-b607-5a90c82b5ef7","ControlNumber":"9709","DisclosureBlock":"&nbsp;<b>H. Shaw, <\/b> None..<br><b>P. Patel, <\/b> None..<br><b>M. Payne, <\/b> None..<br><b>S. Kumar, <\/b> None..<br><b>M. Highley, <\/b> None..<br><b>K. Prasad, <\/b> None..<br><b>R. Board, <\/b> None..<br><b>C. Barlow, <\/b> None..<br><b>S. Danson, <\/b> None..<br><b>R. Miller, <\/b> None..<br><b>G. Goodhew, <\/b> None..<br><b>F. Master, <\/b> None..<br><b>L. Durrant, <\/b> None.","End":"4\/7\/2024 3:55:00 PM","HasWebcast":null,"Highlights":[],"Id":"11402","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"7","PosterboardNumber":"","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT024","PresenterBiography":null,"PresenterDisplayName":"Lindy Durrant, PhD","PresenterKey":"376fd857-7710-46d7-bfde-6aabb23bf244","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT024. A DNA plasmid melanoma cancer vaccine, SCIB1, combined with nivolumab + ipilimumab in patients with advanced unresectable melanoma: Efficacy and safety results from the open-label Phase 2 SCOPE Trial<b><\/b>","SearchResultFooter":"","SearchResultHeader":"Apr  7 2024  3:00PM","SessionId":"663","SessionOnDemand":"False","SessionTitle":"Cancer Vaccines: Ready for Prime Time?","ShowChatLink":"false","Start":"4\/7\/2024 3:45:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"A DNA plasmid melanoma cancer vaccine, SCIB1, combined with nivolumab + ipilimumab in patients with advanced unresectable melanoma: Efficacy and safety results from the open-label Phase 2 SCOPE Trial<b><\/b>","Topics":null,"cSlideId":""},{"Abstract":"There is no abstract associated with this presentation.","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null},{"Icon":null,"Label":"View Video","SubType":null,"Type":"ViewPlayer","Url":null},{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Other","AdditionalFields":[{"Key":"Topics","Value":",,"},{"Key":"Keywords","Value":",,,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":[],"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":". ","CSlideId":"","ControlKey":"748d7000-71e2-4af6-83eb-8580e10b1a6e","ControlNumber":"12148","DisclosureBlock":"","End":"4\/7\/2024 4:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"11847","IsPresentation":"False","IsSessionOrganizer":"False","Keywords":null,"MediaSource":"None","OtherContent":null,"PlayerUrl":null,"PlayerUrlReason":null,"PositionInSession":"8","PosterboardNumber":"","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"","PresenterBiography":null,"PresenterDisplayName":null,"PresenterKey":null,"PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"Discussion","SearchResultFooter":"","SearchResultHeader":"Apr  7 2024  3:00PM","SessionId":"663","SessionOnDemand":"False","SessionTitle":"Cancer Vaccines: Ready for Prime Time?","ShowChatLink":"false","Start":"4\/7\/2024 3:55:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Discussion","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT04-01 Phase I adult clinical trials,,"},{"Key":"Keywords","Value":"Pancreatic cancer,Immunotherapy,Tumor associated macrophages,Cancer vaccine,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>A. Urman<\/b>, Y. Ding, H. Wang, R. A. Burkhart, J. He, E. M. Jaffee, A. K. Narang, D. Le, D. A. Laheru, L. Zheng, A. De Jesus-Acosta; <br\/>Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD","CSlideId":"","ControlKey":"6ba8cd15-e4d1-4c53-b9bd-8c3f76d9de3f","ControlNumber":"10571","DisclosureBlock":"&nbsp;<b>A. Urman, <\/b> None..<br><b>Y. Ding, <\/b> None..<br><b>H. Wang, <\/b> None..<br><b>R. A. Burkhart, <\/b> None.&nbsp;<br><b>J. He, <\/b> <br><b>Abbvie<\/b> Grant\/Contract. <br><b>E. M. Jaffee, <\/b> <br><b>Lustgarten Foundation<\/b> Grant\/Contract, Other, Chief Medical Advisor. <br><b>Bristol-Meyer Squibb<\/b> Grant\/Contract. <br><b>Genentech<\/b> Grant\/Contract. <br><b>AstraZeneca<\/b> Grant\/Contract. <br><b>NextCure<\/b> Other, Paid Consultant. <br><b>Genocea<\/b> Other, Paid Consultant. <br><b>DragonFly<\/b> Other, Paid Consultant. <br><b>Stimit<\/b> Other, Paid Consultant. <br><b>CSTONE<\/b> Other, Paid Consultant. <br><b>Achilles<\/b> Other, Paid Consultant. <br><b>Candel<\/b> Other, Paid Consultant. <br><b>Parker Institute<\/b> Other, Advisory Board Member. <br><b>Break Through Cancer<\/b> Other, Advisory Board Member. <br><b>Abmeta Biotech<\/b> Other, Founder.<br><b>A. K. Narang, <\/b> None.&nbsp;<br><b>D. Le, <\/b> <br><b>The PD-1 Company<\/b> Other, Advisory Board.<br><b>D. A. Laheru, <\/b> None.&nbsp;<br><b>L. Zheng, <\/b> <br><b>Bristol-Meyer Squibb<\/b> Grant\/Contract. <br><b>Merck<\/b> Grant\/Contract. <br><b>AstraZeneca<\/b> Grant\/Contract. <br><b>Amgen<\/b> Grant\/Contract. <br><b>NovaRock<\/b> Grant\/Contract, Other, paid consultant\/Advisory Board Member. <br><b>Abmeta<\/b> Grant\/Contract. <br><b>AbbVie<\/b> Grant\/Contract. <br><b>Biosion<\/b> Other, paid consultant\/Advisory Board Member. <br><b>Alphamab; Mingruizhiyao<\/b> Stock, Other, paid consultant\/Advisory Board Member. <br><b>Ambrx<\/b> Other, paid consultant\/Advisory Board Member. <br><b>Akrevia\/Xilio<\/b> Other, paid consultant\/Advisory Board Member. <br><b>QED Bioscience; Novagenesis<\/b> Other, paid consultant\/Advisory Board Member. <br><b>Cellaration<\/b> Stock. <br><b>Snow Lake Capitals<\/b> Other, paid consultant\/Advisory Board Member. <br><b>Amberstone Biosciences<\/b> Stock, Other, paid consultant\/Advisory Board Member. <br><b>Pfizer<\/b> Other, paid consultant\/Advisory Board Member. <br><b>Tavotek Lab<\/b> Other, paid consultant\/Advisory Board Member. <br><b>Clinical Trial Options, LLC<\/b> Other, paid consultant\/Advisory Board Member. <br><b>Fortress Biotech<\/b> Other, paid consultant\/Advisory Board Member. <br><b>Histosonics<\/b> Other, paid consultant\/Advisory Board Member.<br><b>A. De Jesus-Acosta, <\/b> None.","End":"4\/7\/2024 4:10:00 PM","HasWebcast":null,"Highlights":[],"Id":"11873","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"9","PosterboardNumber":"","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT134","PresenterBiography":null,"PresenterDisplayName":"Arielle Urman","PresenterKey":"8c7ba89b-e57d-4a9d-8dd6-5ee9ebee8c61","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT134. Safety and immunologic impact of neoadjuvant\/adjuvant GM-CSF-secreting allogenic pancreatic tumor cell vaccine (GVAX) combined with cyclophosphamide, pembrolizumab, and macrophage-targeting CSF1R inhibitor IMC-CS4 in pancreatic adenocarcinoma<b><\/b>","SearchResultFooter":"","SearchResultHeader":"Apr  7 2024  3:00PM","SessionId":"663","SessionOnDemand":"False","SessionTitle":"Cancer Vaccines: Ready for Prime Time?","ShowChatLink":"false","Start":"4\/7\/2024 4:00:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Safety and immunologic impact of neoadjuvant\/adjuvant GM-CSF-secreting allogenic pancreatic tumor cell vaccine (GVAX) combined with cyclophosphamide, pembrolizumab, and macrophage-targeting CSF1R inhibitor IMC-CS4 in pancreatic adenocarcinoma<b><\/b>","Topics":null,"cSlideId":""},{"Abstract":"There is no abstract associated with this presentation.","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null},{"Icon":null,"Label":"View Video","SubType":null,"Type":"ViewPlayer","Url":null},{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Other","AdditionalFields":[{"Key":"Topics","Value":",,"},{"Key":"Keywords","Value":",,,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":[],"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":". ","CSlideId":"","ControlKey":"91c8dea0-aa04-4d3b-829e-416d569ec19b","ControlNumber":"12174","DisclosureBlock":"","End":"4\/7\/2024 4:15:00 PM","HasWebcast":null,"Highlights":[],"Id":"11874","IsPresentation":"False","IsSessionOrganizer":"False","Keywords":null,"MediaSource":"None","OtherContent":null,"PlayerUrl":null,"PlayerUrlReason":null,"PositionInSession":"10","PosterboardNumber":"","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"","PresenterBiography":null,"PresenterDisplayName":null,"PresenterKey":null,"PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"Discussion","SearchResultFooter":"","SearchResultHeader":"Apr  7 2024  3:00PM","SessionId":"663","SessionOnDemand":"False","SessionTitle":"Cancer Vaccines: Ready for Prime Time?","ShowChatLink":"false","Start":"4\/7\/2024 4:10:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Discussion","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT04-01 Phase I adult clinical trials,,"},{"Key":"Keywords","Value":"mRNA,Vaccines,Pancreatic cancer,T cell,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"Z. Sethna<sup>1<\/sup>, P. Guasp<sup>1<\/sup>, C. Reiche<sup>1<\/sup>, N. Ceglia<sup>1<\/sup>, E. Patterson<sup>1<\/sup>, M. Milighetti<sup>1<\/sup>, N. Pang<sup>1<\/sup>, G. Payne<sup>1<\/sup>, A. Ohmoto<sup>1<\/sup>, L. Rojas<sup>1<\/sup>, M. Amisaki<sup>1<\/sup>, A. Zebboudj<sup>1<\/sup>, E. Bruno<sup>1<\/sup>, L. Zhang<sup>1<\/sup>, Z. Odgerel<sup>1<\/sup>, C. Cheng<sup>1<\/sup>, E. Derhovanessian<sup>2<\/sup>, L. Manning<sup>2<\/sup>, F. Müller<sup>3<\/sup>, I. Rhee<sup>4<\/sup>, M. Yadav<sup>4<\/sup>, M. Gönen<sup>1<\/sup>, O. Basturk<sup>1<\/sup>, A. Epstein<sup>1<\/sup>, P. Momtaz<sup>1<\/sup>, W. Park<sup>1<\/sup>, R. Sugarman<sup>1<\/sup>, A. Varghese<sup>1<\/sup>, E. Won<sup>1<\/sup>, A. Desai<sup>1<\/sup>, A. C. Wei<sup>1<\/sup>, M. I. D’Angelica<sup>1<\/sup>, T. Kingham<sup>1<\/sup>, K. C. Soares<sup>1<\/sup>, W. R. Jarnagin<sup>1<\/sup>, J. Drebin<sup>1<\/sup>, E. M. O'Reilly<sup>1<\/sup>, I. Mellman<sup>4<\/sup>, U. Sahin<sup>2<\/sup>, Ö. Türeci<sup>2<\/sup>, B. D. Greenbaum<sup>1<\/sup>, <b>V. P. Balachandran<\/b><sup>1<\/sup>; <br\/><sup>1<\/sup>Memorial Sloan Kettering Cancer Center, New York, NY, <sup>2<\/sup>BioNTech, SE, Mainz, Germany, <sup>3<\/sup>BioNTech, Mainz, Germany, <sup>4<\/sup>Genentech, San Francisco, CA","CSlideId":"","ControlKey":"7e46ea6d-2327-4480-b302-ca9318b35409","ControlNumber":"10483","DisclosureBlock":"<b>&nbsp;Z. Sethna, <\/b> <br><b>Inventor on patent applications related to work on antigen cross-reactivity (PCT\/US2023\/011643) and tracking vaccine-expanded T&#8201;cell clones<\/b> Patent.<br><b>P. Guasp, <\/b> None..<br><b>C. Reiche, <\/b> None..<br><b>N. Ceglia, <\/b> None..<br><b>E. Patterson, <\/b> None..<br><b>M. Milighetti, <\/b> None..<br><b>N. Pang, <\/b> None..<br><b>G. Payne, <\/b> None..<br><b>A. Ohmoto, <\/b> None.&nbsp;<br><b>L. Rojas, <\/b> <br><b>Inventor of a patent related to oncolytic viral therapy (US20170051022A1)<\/b> Patent. <br><b>Inventor on patent applications related to work on antigen cross-reactivity (PCT\/US2023\/011643) and tracking vaccine-expanded T&#8201;cell clones<\/b> Patent.<br><b>M. Amisaki, <\/b> None..<br><b>A. Zebboudj, <\/b> None..<br><b>E. Bruno, <\/b> None..<br><b>L. Zhang, <\/b> None..<br><b>Z. Odgerel, <\/b> None..<br><b>C. Cheng, <\/b> None.&nbsp;<br><b>E. Derhovanessian, <\/b> <br><b>BioNTech<\/b> Employment. <br><b>L. Manning, <\/b> <br><b>BioNTech<\/b> Employment. <br><b>F. Müller, <\/b> <br><b>BioNTech<\/b> Employment. <br><b>I. Rhee, <\/b> <br><b>Genentech<\/b> Employment. <br><b>M. Yadav, <\/b> <br><b>Genentech<\/b> Employment.<br><b>M. Gönen, <\/b> None..<br><b>O. Basturk, <\/b> None.&nbsp;<br><b>A. Epstein, <\/b> <br><b>Up-To-Date<\/b> Other, Royalties.<br><b>P. Momtaz, <\/b> None.&nbsp;<br><b>W. Park, <\/b> <br><b>Astellas, Merck, NIH\/NCI, Parker Institute for Cancer Immunotherapy, and Break Through Cancer<\/b> Other, Grant and research support.<br><b>R. Sugarman, <\/b> None.&nbsp;<br><b>A. Varghese, <\/b> <br><b>Bristol-Myers Squibb, GlaxoSmithKline, Lilly Oncology, OBI Pharma, and Silenseed<\/b> Other, Provision of services, uncompensated.<br><b>E. Won, <\/b> None..<br><b>A. Desai, <\/b> None.&nbsp;<br><b>A. C. Wei, <\/b> <br><b>Histosonics and Biosapien<\/b> Other, Consultant. <br><b>Medtronic and AstraZeneca<\/b> Honorarium. <br><b>Intuitive Surgical<\/b> Travel.<br><b>M. I. D’Angelica, <\/b> None.&nbsp;<br><b>T. Kingham, <\/b> <br><b>Olympus Surgical<\/b> One-time consulting fee.<br><b>K. C. Soares, <\/b> None..<br><b>W. R. Jarnagin, <\/b> None.&nbsp;<br><b>J. Drebin, <\/b> <br><b>Alnylam Pharmaceuticals, Arrowroot Acquisition, and Ionis Pharmaceuticals<\/b> Stock. <br><b>E. M. O'Reilly, <\/b> <br><b>Genentech\/Roche, Celgene\/Bristol-Myers Squibb, BioNTech, AstraZeneca, Arcus, Elicio, Parker Institute, and the NIH\/NCI<\/b> Other, Grant and research support. <br><b>I. Mellman, <\/b> <br><b>Genentech<\/b> Employment. <br><b>U. Sahin, <\/b> <br><b>BioNTech<\/b> Other, Co-founder, management board member, and employee. <br><b>Ö. Türeci, <\/b> <br><b>BioNTech<\/b> Other, Co-founder, management board member, and employee. <br><b>B. D. Greenbaum, <\/b> <br><b>Inventor on patent applications related to work on antigen cross-reactivity (PCT\/US2023\/011643) and tracking vaccine-expanded T&#8201;cell clones<\/b> Patent. <br><b>Inventor on a patent application on neoantigen quality modeling (63\/303,500)<\/b> Patent. <br><b>Merck, Bristol Meyers Squibb, and Chugai Pharmaceuticals<\/b> Other, Honoraria for speaking engagements. <br><b>Bristol Meyers Squibb, Merck, and ROME Therapeutics<\/b> Other, Research funding. <br><b>Darwin Health, Merck, PMV Pharma, Shennon Biotechnologies, and Rome Therapeutics<\/b> Other, Consultant. <br><b>V. P. Balachandran, <\/b> <br><b>Inventor on patent applications related to work on antigen cross-reactivity (PCT\/US2023\/011643) and tracking vaccine-expanded T&#8201;cell clones<\/b> Patent. <br><b>Inventor on a patent application on neoantigen quality modeling (63\/303,500)<\/b> Patent. <br><b>Genentech<\/b> Honoraria for speaking engagements. <br><b>Bristol-Myers Squibb and Genentech<\/b> Other, Research support.","End":"4\/7\/2024 4:25:00 PM","HasWebcast":null,"Highlights":[],"Id":"11403","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"11","PosterboardNumber":"","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT025","PresenterBiography":null,"PresenterDisplayName":"Vinod Balachandran, MD","PresenterKey":"d3c09c21-1e4a-4fb0-93ae-d1d7f652caf5","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT025. <b>Personalized RNA neoantigen vaccines induce long-lived CD8<sup>+<\/sup> T effector cells in pancreatic <\/b><b>cancer<\/b>","SearchResultFooter":"","SearchResultHeader":"Apr  7 2024  3:00PM","SessionId":"663","SessionOnDemand":"False","SessionTitle":"Cancer Vaccines: Ready for Prime Time?","ShowChatLink":"false","Start":"4\/7\/2024 4:15:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"<b>Personalized RNA neoantigen vaccines induce long-lived CD8<sup>+<\/sup> T effector cells in pancreatic <\/b><b>cancer<\/b>","Topics":null,"cSlideId":""},{"Abstract":"There is no abstract associated with this presentation.","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null},{"Icon":null,"Label":"View Video","SubType":null,"Type":"ViewPlayer","Url":null},{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Other","AdditionalFields":[{"Key":"Topics","Value":",,"},{"Key":"Keywords","Value":",,,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":[],"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":". ","CSlideId":"","ControlKey":"d7e17f83-6a25-4ac7-be73-25ef30ce9796","ControlNumber":"12149","DisclosureBlock":"","End":"4\/7\/2024 4:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"11848","IsPresentation":"False","IsSessionOrganizer":"False","Keywords":null,"MediaSource":"None","OtherContent":null,"PlayerUrl":null,"PlayerUrlReason":null,"PositionInSession":"12","PosterboardNumber":"","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"","PresenterBiography":null,"PresenterDisplayName":null,"PresenterKey":null,"PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"Discussion","SearchResultFooter":"","SearchResultHeader":"Apr  7 2024  3:00PM","SessionId":"663","SessionOnDemand":"False","SessionTitle":"Cancer Vaccines: Ready for Prime Time?","ShowChatLink":"false","Start":"4\/7\/2024 4:25:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Discussion","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++PL03-01 First-in-human phase I trials,,"},{"Key":"Keywords","Value":"Immunotherapy,Prostate cancer,Combination therapy,Cancer immunotherapy,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>C. J. Link, Jr.<\/b><sup>1<\/sup>, C. E. Vargas<sup>2<\/sup>, S. Kee<sup>3<\/sup>, G. C. Prendergast<sup>1<\/sup>, M. Mautino<sup>3<\/sup>, G. R. Rossi<sup>3<\/sup>, D. Vaughan<sup>4<\/sup>, R. Harris<sup>5<\/sup>, J. Williams<sup>2<\/sup>, J. J. Lewis<sup>1<\/sup>; <br\/><sup>1<\/sup>Lankenau Institute for Medical Research, Wynnewood, PA, <sup>2<\/sup>Williams Cancer Institute, Beverly Hills, CA, <sup>3<\/sup>Syncromune, Fort Lauderdale, FL, <sup>4<\/sup>University of Florida College of Medicine, Gainsville, FL, <sup>5<\/sup>UroPartners, Chicago, IL","CSlideId":"","ControlKey":"97a20514-afc7-4614-b80a-282d1c58c0e2","ControlNumber":"10410","DisclosureBlock":"<b>&nbsp;C. J. Link, <\/b> <br><b>Syncromune<\/b> Employment, Fiduciary Officer, Stock, Stock Option. <br><b>Novascan Inc.<\/b> Other, Board member. <br><b>QSAM Bioscience, Inc.<\/b> Other, Board Member.<br><b>C. E. Vargas, <\/b> None.&nbsp;<br><b>S. Kee, <\/b> <br><b>syncromune<\/b> Independent Contractor, Stock Option. <br><b>G. C. Prendergast, <\/b> <br><b>Augen Therapeutics<\/b> Fiduciary Officer, Stock. <br><b>Dynamis Therapeutics<\/b> Stock, Advisor. <br><b>MBF Therapeutics<\/b> Stock. <br><b>Meditope Biosciences<\/b> Fiduciary Officer, Stock. <br><b>Ribonova<\/b> Stock, Advisor. <br><b>Syncromune<\/b> Stock, Advisory Board. <br><b>Immunome<\/b> Stock, Advisor. <br><b>Merck<\/b> Stock. <br><b>M. Mautino, <\/b> <br><b>Syncromune<\/b> Employment, Stock. <br><b>G. R. Rossi, <\/b> <br><b>Syncromune<\/b> Employment, Stock, Stock Option. <br><b>D. Vaughan, <\/b> <br><b>Syncromune<\/b> Independent Contractor, Stock Option, Advisory Board. <br><b>Abvie<\/b> Stock. <br><b>Roche<\/b> Stock. <br><b>Novartis<\/b> Stock. <br><b>Lilly<\/b> Stock. <br><b>Merck<\/b> Stock. <br><b>Merck KgA<\/b> Stock. <br><b>R. Harris, <\/b> <br><b>Syncromune<\/b> Independent Contractor, Stock Option. <br><b>J. Williams, <\/b> <br><b>Syncromune<\/b> Stock. <br><b>J. J. Lewis, <\/b> <br><b>Syncromune<\/b> Employment, Stock. <br><b>Merlin Biotech<\/b> Stock Option, Scientific Advisory Board. <br><b>Roche<\/b> Stock. <br><b>Eli Lilly<\/b> Stock, Advisory Board. <br><b>ASP Isotopes<\/b> Stock, Advisory Board. <br><b>Novartis<\/b> Stock, Other Securities, Advisory Board. <br><b>Merck<\/b> Stock.","End":"4\/7\/2024 4:40:00 PM","HasWebcast":null,"Highlights":[],"Id":"11404","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"13","PosterboardNumber":"","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT026","PresenterBiography":null,"PresenterDisplayName":"Charles Link, MD","PresenterKey":"b66500bd-43ec-4073-a3b3-6acaab8b2407","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT026. Systemic responses to SYNC-T therapy: <i>In situ<\/i> personalized cancer vaccination with intratumoral infusion of multitarget immunotherapy in patients with metastatic castrate-resistant prostate cancer (mCRPC)","SearchResultFooter":"","SearchResultHeader":"Apr  7 2024  3:00PM","SessionId":"663","SessionOnDemand":"False","SessionTitle":"Cancer Vaccines: Ready for Prime Time?","ShowChatLink":"false","Start":"4\/7\/2024 4:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Systemic responses to SYNC-T therapy: <i>In situ<\/i> personalized cancer vaccination with intratumoral infusion of multitarget immunotherapy in patients with metastatic castrate-resistant prostate cancer (mCRPC)","Topics":null,"cSlideId":""},{"Abstract":"There is no abstract associated with this presentation.","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null},{"Icon":null,"Label":"View Video","SubType":null,"Type":"ViewPlayer","Url":null},{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Other","AdditionalFields":[{"Key":"Topics","Value":",,"},{"Key":"Keywords","Value":",,,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":[],"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":". ","CSlideId":"","ControlKey":"677ddd9b-ef98-4432-857d-96595f673af2","ControlNumber":"12150","DisclosureBlock":"","End":"4\/7\/2024 4:45:00 PM","HasWebcast":null,"Highlights":[],"Id":"11849","IsPresentation":"False","IsSessionOrganizer":"False","Keywords":null,"MediaSource":"None","OtherContent":null,"PlayerUrl":null,"PlayerUrlReason":null,"PositionInSession":"14","PosterboardNumber":"","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"","PresenterBiography":null,"PresenterDisplayName":null,"PresenterKey":null,"PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"Discussion","SearchResultFooter":"","SearchResultHeader":"Apr  7 2024  3:00PM","SessionId":"663","SessionOnDemand":"False","SessionTitle":"Cancer Vaccines: Ready for Prime Time?","ShowChatLink":"false","Start":"4\/7\/2024 4:40:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Discussion","Topics":null,"cSlideId":""}]